SynthesisOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2007
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.
Synthesis in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Fracture prevention in postmenopausal women.BMJ clinical evidence · 2011Pooled it
- Pooled it
- Pooled it
- Effects of treatment with fluoride on bone mineral density and fracture risk--a meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2008Pooled it
- Effects of teriparatide in Chinese and Caucasian women with osteoporosis: bridging study on efficacy.Clinical interventions in aging · 2019Trial
- Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate.Calcified tissue international · 2017Article
- A retrospective analysis of nonresponse to daily teriparatide treatment.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016Article
- Femoral volumetric bone density, geometry, and strength in relation to 25-hydroxy vitamin D in older men.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2015Article
- The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug.BioMed research international · 2014Article
- The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy.Archives of medical science : AMS · 2013Article
- Effects of kalsis, a dietary supplement, on bone metabolism in the ovariectomized rats.Journal of osteoporosis · 2012Article
- Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis.International journal of women's health · 2010Article
- Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2010Article
- Current and emerging therapies for the treatment of osteoporosis.Journal of experimental pharmacology · 2010Review
- Prevention of osteoporosis-related fractures among postmenopausal women and older men.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2009Review
- Loss of life years after a hip fracture.Acta orthopaedica · 2009Article
- Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2008Article
- The diagnosis and treatment of primary osteoporosis according to current guidelines.Deutsches Arzteblatt international · 2008Article
- Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts.The Journal of biological chemistry · 2008Article
- [Metabolic bone diseases].Der Internist · 2007Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe effects of parathyroid hormone (PTH) alone or in combination with antiresorptive therapy on changes in bone mineral density (BMD) and fracture risk were studied. MATERIALS AND
methodsRandomised placebo controlled trials were retrieved from the PubMed, Web of Science or Embase databases.
resultsPTH alone or in combination with antiresorptive drugs reduced vertebral [relative risk (RR)=0.36, 95% confidence interval (CI): 0.28-0.47, 2p<0.01] and non-vertebral (RR=0.62, 95% CI: 0.48-0.82, 2p<0.01) fracture risk and increased spine BMD by 6.6% (95% CI: 5.2-8.1%, 2p<0.01) and hip BMD non-significantly by 1.0% (95% CI: -0.1 to 2.1%, 2p=0.08) during 11-36 months of follow-up (13 trials). The gain in spine and hip BMD tended to increase with the length of the PTH treatment. No significant effect of study duration on fracture risk could be demonstrated. The major adverse events were hypercalcaemia, nausea and discomfort at the injection sites. Only limited data are currently available on fracture risk reduction with PTH plus antiresorptive therapies.
conclusionAlthough the number of studies on non-vertebral fractures is limited, our pooled analysis revealed that PTH alone or in combination with antiresorptive drugs would appear to be able to reduce the risk of vertebral and non-vertebral fractures and to increase spine and perhaps hip BMD. However, these analyses were based on cross-sectional data--i.e. based on indirect comparisons--and further studies with a direct comparison of study duration are necessary. No studies comparing PTH, PTH plus antiresorptive drugs and antiresorptive drug versus placebo in a factorial design are available; consequently, we were unable to draw any conclusions on the superiority of PTH plus antiresorptive drug versus antiresorptive drug or PTH alone with respect to BMD or fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.